{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:18Z","timestamp":1793726058415,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100024990","name":"National Yang Ming Chiao Tung University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST111-2314-B002-082-MY3"],"award-info":[{"award-number":["MOST111-2314-B002-082-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1053\/j.ajkd.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:17:10Z","timestamp":1745925430000},"page":"301-313.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium\/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD"],"prefix":"10.1053","volume":"86","author":[{"given":"Yen-Chieh","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hsuin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ajkd.2025.03.016_bib1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"10225","key":"10.1053\/j.ajkd.2025.03.016_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1053\/j.ajkd.2025.03.016_bib3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.03.016_bib4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"10.1053\/j.ajkd.2025.03.016_bib5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.ajkd.2025.03.016_bib6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.016_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.016_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2025.03.016_bib9","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2025.03.016_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109146","article-title":"Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with\/without albuminuria: a systematic review and network meta-analysis","volume":"183","author":"Kawai","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"17","key":"10.1053\/j.ajkd.2025.03.016_bib11","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1053\/j.ajkd.2025.03.016_bib12","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.2337\/dc20-1231","article-title":"Comparative effectiveness of the sodium-glucose cotransporter 2 inhibitor empagliflozin versus other antihyperglycemics on risk of major adverse kidney events","volume":"43","author":"Xie","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1053\/j.ajkd.2025.03.016_bib13","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","article-title":"Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes","volume":"84","author":"Edmonston","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.016_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-021-01258-x","article-title":"Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","volume":"20","author":"Lugner","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.ajkd.2025.03.016_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109231","article-title":"Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists","volume":"185","author":"Kobayashi","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1053\/j.ajkd.2025.03.016_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.14598","article-title":"The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a Scandinavian cohort study","volume":"24","author":"Ueda","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.ajkd.2025.03.016_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101510","article-title":"Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: a real-world population-based analysis","volume":"50","author":"Lui","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.016_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12916-024-03483-z","article-title":"Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes","volume":"22","author":"Sohn","year":"2024","journal-title":"BMC Med"},{"key":"10.1053\/j.ajkd.2025.03.016_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/CLEP.S286572","article-title":"Existing data sources in clinical epidemiology: the Taiwan National Health Insurance Laboratory Databases","volume":"13","author":"Lee","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.03.016_bib21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.016_bib22","first-page":"15","article-title":"Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization","volume":"14","author":"Young","year":"2008","journal-title":"Am J Manag Care"},{"issue":"6","key":"10.1053\/j.ajkd.2025.03.016_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1053\/j.ajkd.2025.03.016_bib24","article-title":"Association of entirely claims-based frailty indices with long-term outcomes in patients with acute myocardial infarction, heart failure, or pneumonia: a nationwide cohort study in Turkey","volume":"10","author":"Kundi","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.016_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10654-018-0447-z","article-title":"A comparison of different methods to handle missing data in the context of propensity score analysis","volume":"34","author":"Choi","year":"2019","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.03.016_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"8","key":"10.1053\/j.ajkd.2025.03.016_bib27","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1177\/0962280218781171","article-title":"Propensity score weighting analysis and treatment effect discovery","volume":"28","author":"Mao","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"23","key":"10.1053\/j.ajkd.2025.03.016_bib28","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1053\/j.ajkd.2025.03.016_bib29","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.jval.2019.06.010","article-title":"Propensity score weighting using overlap weights: a new method applied to regorafenib clinical data and a cost-effectiveness analysis","volume":"22","author":"Mlcoch","year":"2019","journal-title":"Value Health"},{"issue":"26","key":"10.1053\/j.ajkd.2025.03.016_bib30","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1002\/sim.8355","article-title":"Avoiding pitfalls when combining multiple imputation and propensity scores","volume":"38","author":"Granger","year":"2019","journal-title":"Stat Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.03.016_bib31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.016_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12933-020-01197-z","article-title":"Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","volume":"20","author":"Yamada","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.03.016_bib33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.03.016_bib34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MNH.0000000000000894","article-title":"Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease","volume":"32","author":"Alicic","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"23","key":"10.1053\/j.ajkd.2025.03.016_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235831","article-title":"Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes","volume":"20","author":"Nin\u010devi\u0107","year":"2019","journal-title":"Int J Mol Sci"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625008315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625008315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:25:07Z","timestamp":1762280707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625008315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0272638625008315"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.03.016","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium\/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}